SINGAPORE CLINICAL RESEARCH INSTITUTE

Singapore Clinical Trials Symposium 2026: Asia Charts Path to Become Global Epicenter for Clinical Research

- SCRI Clinical Trials Symposium 2026 convened in Singapore on July 30, marking SCRI's 30th anniversary with a focus on positioning Asia as a leading clinical trial destination. - Three Memoranda of Understanding were signed, including a partnership with AstraZeneca to bring innovative trials in ADCs, cell and gene therapies, and bispecific antibodies to Singapore over five years. - STCC Executive Director Wee Joo Chng emphasized that Asia has the patients, unmet medical needs, top-class science, and infrastructure to become a global clinical trial epicenter. - Key next steps include parallel evolution of regulatory frameworks, embracing new trial endpoints, synthetic data, digital twins, and incorporation of AI in clinical research.